IDO1 and neoplasm: In tumors overexpressing IDO/TDO, the tryptophan metabolite l-kynurenine activates the aryl hydrocarbon receptor (AHR) pathway, leading to increased immunosuppression via Tregs and tumor-associated macrophages, and enhanced PD-1 expression on CD8+ T cells.